Using unconjugated antibodies as an immunotherapeutic approach to treatment of B-cell neoplasms.
B-cell neoplasms have the sixth highest mortality incidence and one of the largest rates of increase of all malignancies. Frequent relapse and the development of refractory disease in this patient group have stimulated research to find alternative treatments. The use of unconjugated antibodies offers a new approach to the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. This article will explore the pharmacology, dosage, and administration guidelines as well as side effect management of the available drugs in this classification. Expectations for future approaches to the treatment of B-cell neoplasms will be discussed.
Flores
Aurea M
AM
Center for Cancer Care, University Community Hospital, Tampa, FL 33613, USA. aflores@mail.uch.org
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents